Are peptides legal? A status tracker

Status by compound

44 compounds

FDA: approval as a medicine in the US. US pharmacies: whether a state-licensed compounding pharmacy may make it under FDA's rules for bulk ingredients. Sport: the World Anti-Doping Agency's list, which most sports follow. Australia: the national Poisons Standard. Each compound's page explains its status in full.

What changed recently

• 6 Oct 2026FDA posted warning letters, dated 23 and 24 September 2026, to two websites selling unapproved injectable semaglutide to US consumers, including products called “Semanext Injection” and “Semanat Injection”, and asked both to stop selling unapproved and misbranded drugs to US consumers⁵⁶.
• 6 Oct 2026Australia’s TGA said it had issued 12 infringement notices totaling A$126,720 over the alleged unlawful importing and advertising of prescription medicines, including three to two Victoria-based people over Mounjaro (tirzepatide) pens they allegedly imported⁷.
• 1 Oct 2026Greenwich Rx, a compounding pharmacy in Texas, recalled some lots of its compounded glutathione injection because endotoxin levels might be too high, warning that such injections could cause fever, shock and death¹²⁵.
• 29 Sep 2026The US Justice Department announced that a federal grand jury in Florida had charged two Indian nationals with conspiracy and smuggling over an alleged scheme to sell counterfeit Ozempic, a brand of semaglutide, to US distributors; one of them, extradited from Italy, first appeared in court that day. An indictment is only an allegation¹¹⁸.
• 28 Sep 2026Australia’s Therapeutic Goods Administration (TGA) announced Federal Court proceedings against two former directors of BioV8 and, if the court grants leave, the former company, now in liquidation, alleging unlawful advertising of peptides such as BPC-157 and CJC-1295 between June 2024 and July 2025²³.
• 25 Sep 2026In late September 2026 Health Canada posted a second dose-display recall of Apo-Semaglutide, Apotex’s generic semaglutide pen, because one lot may show and deliver a lower dose than expected; the first, posted on 27 August, involved a lot that could deliver a higher dose than expected^126127128.
• 21 Sep 2026WADA published its 2027 Prohibited List, in force from 1 January 2027; it keeps BPC-157, TB-500, CJC-1295 and ipamorelin banned and adds the word “peptides” to its section on unapproved substances⁴⁰⁴⁵.
• 18 Sep 2026A federal jury in New Haven, Connecticut, convicted one of the two people who ran Pinned Aminos, which sold drugs labeled for research use; the other had pleaded guilty and was sentenced in August to three years’ probation²⁶.
• 27 Aug 2026The US Court of Appeals for the Fifth Circuit upheld FDA’s decisions ending the tirzepatide and semaglutide shortages, which had allowed mass compounding of both drugs³⁴¹²⁹.
• 24 Aug 2026FDA sent warning letters to online peptide sellers, saying “research” products including PT-141, tesamorelin and a semaglutide product were unapproved new drugs^21222325130.
• 24 Jul 2026The UK’s medicines regulator, the MHRA, said retatrutide has not been authorized for use in the UK, “meaning anyone selling this product is doing so illegally”¹³¹.
• 23 Jul 2026FDA’s Pharmacy Compounding Advisory Committee voted to recommend letting pharmacies compound BPC-157, TB-500 and MOTS-c, against the advice of FDA staff; its votes only advise FDA^1011132.
• 23 Jul 2026Federal prosecutors in Michigan announced a 21-month prison sentence for a man who sold misbranded drugs from China, including semaglutide and tirzepatide, through websites that called them “for research purposes only”²⁷.
• 17 Jun 2026FDA sent a warning letter to an online seller saying its “research” gonadorelin was an unapproved new drug; labels such as “RESEARCH USE ONLY” did not change that the products were meant for people¹³³.
• 15 Apr 2026FDA said it would remove 12 peptides, including BPC-157, TB-500 and MOTS-c, from Category 2, its list of ingredients that may present significant safety risks, because their nominators had withdrawn the nominations; a law firm notes that this does not make them eligible for compounding¹⁶⁵².
• 9 Apr 2026Health Canada warned against injecting peptides bought online, named BPC-157, TB-500, MOTS-c and retatrutide among unauthorized products it has seized, and said “research use only” labels do not make such products legal¹³⁴.

What does US law say about buying research peptides?

FDA’s 2026 warning letters told online sellers that “research” peptides they sold for people, such as PT-141 and gonadorelin, were unapproved new drugs^{21222325130133}. The 2026 US criminal cases cited here were against sellers: a jury convicted one of the two people who ran websites selling drugs labeled for research use, and a Michigan seller got 21 months in prison²⁶²⁷.

BPC-157, CJC-1295, ipamorelin and melanotan II are not federal controlled substances¹³⁵. Imports are another matter: FDA’s Import Alert 66-41 lets it detain some melanotan, ipamorelin and PT-141 shipments without examining them⁶⁴. FDA says that in most circumstances it is illegal for individuals to import unapproved drugs for personal use, though its staff may make exceptions in limited situations⁴.

What does “for research use only” mean?

It is a label: online sellers offer peptides such as BPC-157 and tesamorelin in vials marked “research use only”¹⁰²¹. FDA says labels like “research purpose only” and “not for human consumption” do not stop a product from being a drug when the evidence shows it is meant for people²³²⁴.

• FDA’s August 2026 warning letters said sellers’ own websites, including a “peptide calculator”, a “peptide guide” and comparison posts, showed their “research use only” vials were really sold for people²¹²²²⁵.
• On 18 September 2026 a federal jury in New Haven, Connecticut, convicted one of the two people who ran Pinned Aminos, whose website carried what prosecutors called a false disclaimer that its products were “intended for laboratory and research use only”; the other had pleaded guilty in April and was sentenced in August to three years’ probation²⁶.
• Eli Lilly’s August 2026 lawsuits target sellers that it says falsely claim their retatrutide is for “research-use only” when it is meant for people¹³.
• Health Canada says research-use-only labeling “does not make these products legal”, and an MHRA official told the Guardian that the UK regulator disregards “research purposes” claims used to get around medicines rules¹³⁴¹³⁶.

Why can’t US pharmacies make BPC-157 and other popular peptides?

Under section 503A of federal drug law, a compounding pharmacy may make a drug from a bulk ingredient only if the ingredient passes one of three tests¹⁴. It must meet a USP monograph (a published quality standard), be part of an FDA-approved drug, or be on FDA’s 503A bulks list¹⁴. While FDA builds that list, it sorts nominated ingredients into categories¹⁵. For Category 1, FDA does not intend to act against pharmacies that use the ingredient while it is evaluated, which is not approval¹⁴. Category 2 holds ingredients that FDA says “may present significant safety risks”¹⁶.

BPC-157, TB-500, MOTS-c, CJC-1295, ipamorelin, melanotan II and PEG-MGF are in no 503A category, so pharmacies have no lawful route to compound them¹⁵⁵². Under FDA’s separate policy for outsourcing facilities (503B), ipamorelin is in Category 2, the list of ingredients that may present significant safety risks¹⁶. In July 2026 FDA’s advisers voted to recommend adding BPC-157, TB-500 and MOTS-c to the 503A bulks list. The votes only advise FDA, which has said it will announce any final decision through notice-and-comment rulemaking; in the meantime it could also place them in Category 1 of its interim policy⁵²¹³². As of 8 October 2026 it had done neither: the three were still in no category, FDA had posted no minutes of the meeting, and no proposed rule had appeared in the Federal Register^15137138.

• CJC-1295 and ipamorelin: FDA’s advisers voted against allowing both in late 2024¹²⁰¹³⁹.
• Kisspeptin-10: in Category 2 since September 2023 and still there in the list updated in May 2026, so FDA says it would consider acting against a pharmacy that compounds it¹⁴¹⁵¹⁶.
• Pentadeca arginate: sold as an arginine salt of BPC-157, it is in no 503A category, and FDA’s July 2026 review of BPC-157 covered only the free base and the acetate salt. FDA told its advisers that other salts “must be evaluated for eligibility”, so by our reading pharmacies may not make it^1015113140.
• GHK-Cu: non-injectable forms, such as topical products, are in Category 1, so FDA does not intend to act against pharmacies that compound them under its interim policy; injectable GHK-Cu is in no category¹⁴¹⁵¹⁶.
• GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF: FDA plans to consult its advisers on all five at a meeting before the end of February 2027¹⁵¹⁴¹.
• Glutathione and NAD+: both are in Category 1, so for now FDA does not intend to act against pharmacies that compound them under the conditions of its interim policy¹⁴¹⁵.
• Semaglutide and tirzepatide: now that the shortages are over, pharmacies may no longer make routine copies of these approved drugs³⁰.
• Retatrutide and cagrilintide: FDA says they “cannot be used in compounding under federal law”¹⁷.
• Tesamorelin: FDA says biologics cannot be compounded and lists Egrifta, the approved tesamorelin, as a biologic, so by our reading pharmacies have no route; FDA has issued no tesamorelin-specific notice⁶⁷⁶⁸.
• Thymosin beta-4: in a January 2026 warning letter to an outsourcing facility, FDA said thymosin beta-4 is a biological product, and that biological products are not eligible for the exemptions that let pharmacies and outsourcing facilities compound drugs⁵⁶.
• Sermorelin, gonadorelin and PT-141: an FDA list flags sermorelin and gonadorelin as components of approved drugs, USP publishes a quality standard for gonadorelin acetate, and bremelanotide (PT-141) is the active ingredient of Vyleesi⁵⁷⁸¹⁸⁴. By our reading, that gives pharmacies a possible route for all three, but FDA has not said so for any of them¹⁴.

Semaglutide and tirzepatide are covered in our guide to compounded GLP-1s: routine copies ended when FDA declared their shortages over, and in August 2026 a federal appeals court upheld both decisions^3034129.

Which peptides are FDA-approved drugs?

• Semaglutide: Ozempic, Wegovy and Rybelsus¹⁸.
• Tirzepatide: Mounjaro and Zepbound¹⁹.
• Liraglutide: Victoza, approved in 2010 for type 2 diabetes, and Saxenda, approved in 2014 for weight management; generic versions are approved too^37142143.
• Tesamorelin: Egrifta, approved in 2010 to reduce excess belly fat in adults with HIV and lipodystrophy (abnormal changes in body fat)²⁰⁶⁵.
• Bremelanotide (PT-141): Vyleesi, approved in 2019 for low sexual desire in women before menopause⁸¹¹⁴⁴.
• Oxytocin: Pitocin and generic injections, used in hospitals to start or strengthen labor and to control bleeding after birth¹⁰⁴¹⁰⁵. The nasal sprays and lozenges that telehealth companies sell are made by compounding pharmacies and are not FDA-approved⁶⁷¹⁴⁵.
• Elamipretide (SS-31): Forzinity, given accelerated approval in 2025 to improve muscle strength in people with Barth syndrome, a rare inherited disease, who weigh at least 30 kg⁹⁴¹⁴⁶.
• Afamelanotide (melanotan I): Scenesse, an implant approved in 2019 for adults with erythropoietic protoporphyria, a rare disorder that makes sunlight painful¹⁴⁷¹⁴⁸.
• Sermorelin: once approved as Geref, but its maker stopped selling it in 2008 and FDA withdrew the approvals in 2009⁷¹⁷³.
• Gonadorelin: Factrel, approved in 1982 as a single injection to test the pituitary gland, and Lutrepulse, approved in 1989 and given in pulses by a pump, are both listed as discontinued; gonadorelin injections remain approved for cattle^8283149150.

An approval covers the approved medicine, not “research” vials of the same peptide, which FDA has not checked for quality²³¹⁴⁴. FDA’s 2026 warning letters called “research” PT-141, tesamorelin and semaglutide products unapproved new drugs²¹²²²³.

BPC-157, pentadeca arginate, TB-500, thymosin beta-4, PEG-MGF, MOTS-c, CJC-1295, ipamorelin, melanotan II, retatrutide and cagrilintide are not FDA-approved^{1011121332515355626970}. GHK-Cu, glutathione and NAD+ are not FDA-approved drugs either, though GHK-Cu is sold as a cosmetic ingredient and glutathione as a supplement pill^57585992. Lilly plans to seek FDA approval for retatrutide in the first quarter of 2027, and Novo Nordisk expects an FDA decision in late 2026 on CagriSema, which contains cagrilintide¹⁵¹¹⁵².

Are peptides banned in sport?

Many are: WADA’s Prohibited List bans BPC-157 at all times under S0, its section for substances with no current government approval for human use²⁸. In its section on peptide hormones and growth factors, it bans thymosin beta-4, TB-500 and mechano growth factors (MGFs), including the pegylated form sold as PEG-MGF, under S2.3; AOD-9604 under S2.2.3; and CJC-1295, ipamorelin, MK-677, sermorelin, tesamorelin, GHRP-2, GHRP-6 and hexarelin under S2.2.4²⁸¹⁵³. It bans gonadorelin and kisspeptin for male athletes under S2.2.1, and MOTS-c for all athletes under S4.4.1; the 2027 List keeps all of these bans²⁸⁴⁰.

Under the rules of the US Anti-Doping Agency (USADA), using or possessing a non-Specified substance, the stricter class that includes everything in S2, brings a default four-year ban²⁸¹⁵⁴. A US triathlete received a four-year ban in 2025 for possessing and using BPC-157 and TB-500 and for encouraging followers to buy and use banned substances; the ban was one year shorter than the five years USADA had sought because the athlete admitted the violations and accepted the sanction within 20 days¹⁵⁴. In 2024 an arbitrator banned a US short track speed skater for one year after USADA charged the athlete with using BPC-157 and DHEA, another banned substance; the athlete had declared taking a supplement whose label listed ‘BPC-157 Arginate Salt’, the form sold as pentadeca arginate, and a laboratory found both substances in its capsules⁵⁴. USADA says a therapeutic use exemption (TUE), the permission that lets an athlete use a banned substance for medical reasons, is unlikely to be approved for BPC-157¹⁵⁵.

• Semaglutide and tirzepatide are not banned; WADA tracks them in its Monitoring Program²⁸³¹.
• Bremelanotide (PT-141), elamipretide (SS-31), liraglutide, oxytocin and orforglipron are not named; each is approved in the US, so by our reading they fall outside S0^28404681.
• Afamelanotide (melanotan I) is not named; it is approved in the US and the EU, so by our reading it falls outside S0^2863156.
• Cerebrolysin, DSIP, mazdutide, selank, thymalin, thymosin alpha-1 and VIP are not named, and each is approved as a medicine in at least one country, so by our reading they fall outside S0 too^{2840414596102106115117122}.
• Glutathione and NAD+ are not named, but IV infusions or injections of more than 100 mL in 12 hours are banned unless given during hospital treatment, surgery or clinical tests²⁸.
• Retatrutide, cagrilintide, survodutide, melanotan II, dihexa, epitalon, KPV and LL-37 are not named, but by our reading they fall under S0²⁸⁴⁰⁶¹.
• GHK-Cu is not named, and whether S0 covers it is unclear²⁸⁶⁰. Semax, approved in Russia, is not named either; by our reading it falls outside S0, but whether S2’s ban on corticotrophins and similar substances covers it is unclear^{2840110111157}.

Are peptides legal in Australia?

Australia’s Poisons Standard, in the version in force from 1 October 2026, lists BPC-157, TB-500, thymosin beta-4, AOD-9604, CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin and MK-677 (ibutamoren) as prescription-only medicines (Schedule 4)²⁹. It also lists them in Appendix D, clause 5, “poisons for which possession without authority is illegal”, so under state and territory law they must not be possessed without authority, such as a prescription²⁹. It does not name pentadeca arginate, but it says a reference to a substance includes every salt of it, so its BPC-157 entries also cover pentadeca arginate, which is sold as an arginine salt of BPC-157²⁹¹⁴⁰. These controls are not new: TB-500, CJC-1295 and ipamorelin were already prescription-only and in Appendix D in the standard in force from 1 February 2023, and BPC-157, absent from the standard in force from 1 February 2024, was added to both from 1 June 2024⁸⁹¹⁵⁸. Melanotan II, semaglutide, tirzepatide, liraglutide, afamelanotide (melanotan I), oxytocin, VIP, gonadorelin, sermorelin and injectable glutathione are prescription-only too, but none of them is named in Appendix D; by our reading, sermorelin may still be covered, because the clause 5 entry for growth hormone releasing hormones includes “those separately specified in Schedule 4”²⁹.

The standard does not name MOTS-c, NAD+, bremelanotide or kisspeptin, and we have not established how it applies to tesamorelin or GHK-Cu, or whether its entry for insulin-like growth factors covers PEG-MGF²⁹. In a September 2026 safety advisory, reported by ABC News and republished by Pharmacy Today, the TGA said retatrutide has not been approved by it or by any comparable international regulator¹⁵⁹¹⁶⁰.

• In October 2026 the TGA said two Victoria-based people had been issued infringement notices of A$7,920 and A$3,960 over the alleged importing of Mounjaro (tirzepatide) pens; all 12 notices in that announcement, totaling A$126,720, were paid between July and September 2026⁷.
• In late September 2026 the TGA began Federal Court proceedings over BioV8’s alleged peptide advertising, seeking declarations and financial penalties; the case against the company, now in liquidation, needs the court’s permission²³.
• In August 2026, 7NEWS reported that the TGA had seized a melanotan II nasal spray whose tested doses varied widely¹⁶¹. It also reported that a New South Wales individual had received 27 infringement notices totaling A$101,412 for allegedly supplying melanotan II¹⁶¹.
• In September 2026 the TGA said in a safety advisory, reported by ABC News, that it had received a report of a torn esophagus linked to a product sold as retatrutide; its tests of a sample in the original unmarked vial found undeclared semaglutide and no retatrutide¹⁵⁹¹⁶⁰.

What about the UK and Canada?

• UK: the Guardian reported in April 2026 that the Medicines and Healthcare products Regulatory Agency (MHRA) was investigating whether UK clinics break the law with claims about the benefits of experimental peptide therapies. An MHRA spokesperson told the paper that peptide injections offered with medicinal claims are treated as medicines, and an MHRA official said the agency disregards “research purposes” claims used to avoid medicines rules¹³⁶.
• UK: the MHRA says anyone selling retatrutide there is “doing so illegally”, and in October 2025 it announced that it had seized more than 2,000 unlicensed retatrutide and tirzepatide pens at an illegal production site in Northampton¹³¹¹⁶².
• Canada: Health Canada says peptides are generally regulated as prescription drugs, and that “research use only” labels do not make such products legal¹³⁴. It has seized unauthorized injectable peptides, including BPC-157, TB-500, thymosin beta-4, MOTS-c and retatrutide¹³⁴¹⁶³.
• Canada: in May 2026 a supplier recalled GHK-Cu and BPC-157 powders sold to compounding and community pharmacies as unauthorized active ingredients¹⁶⁴.
• Canada: gonadorelin is on Health Canada’s Prescription Drug List, and none of the seven human gonadorelin products in its drug database is marketed¹⁶⁵¹⁶⁶.

Questions people ask

Sources

1. 1Two Indian Nationals Charged in Connection with Transnational Counterfeit Ozempic Scheme US Department of Justice, Office of Public Affairs, 29 Sep 2026. justice.gov
2. 2BioV8 Firm, Directors to Face Court Over Alleged Peptide Ads Mirage News (republished Therapeutic Goods Administration release), 29 Sep 2026. miragenews.com
3. 3TGA takes action over social media peptide promotion AJP (Australian Journal of Pharmacy), 28 Sep 2026. ajp.com.au
4. 4Personal Importation U.S. Food and Drug Administration, 18 Aug 2025. fda.gov
5. 5Warning letter to Cheap Medicine Shop, www.cheapmedicineshop.com (MARCS-CMS 737810) U.S. Food and Drug Administration, 24 Sep 2026. fda.gov
6. 6Warning letter to Online Generic Medicine, www.onlinegenericmedicine.com (MARCS-CMS 737806) U.S. Food and Drug Administration, 23 Sep 2026. fda.gov
7. 7More Than $126K in Notices for Illegal Prescription Drug Imports and Ads Mirage News (republished Therapeutic Goods Administration release), 6 Oct 2026. miragenews.com
8. 8Therapeutic Goods (Poisons Standard—February 2023) Instrument 2023 (F2023L00067) Federal Register of Legislation, Australian Government, 31 Jan 2023. legislation.gov.au
9. 9Therapeutic Goods (Poisons Standard—February 2024) Instrument 2024 (F2024L00095) Federal Register of Legislation, Australian Government, 19 Jan 2024. legislation.gov.au
10. 10FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
11. 11FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: TB-500-related bulk drug substances U.S. Food and Drug Administration, 15 May 2026. fda.gov
12. 12July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate) U.S. Food and Drug Administration, 11 May 2026. fda.gov
13. 13Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market Eli Lilly and Company (PR Newswire), 12 Aug 2026. prnewswire.com
14. 14Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
15. 15Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
16. 16Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
17. 17FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
18. 18Drugs@FDA: applications containing semaglutide (NDA 209637, 213051, 213182, 215256, 218316; ANDA 220314) U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
19. 19Drugs@FDA via openFDA: approval history for NDA 215866 (Mounjaro) and NDA 217806 (Zepbound) U.S. Food and Drug Administration (openFDA), accessed 1 Oct 2026. api.fda.gov · data query
20. 20Drugs@FDA: BLA 022505, Egrifta (tesamorelin acetate) U.S. Food and Drug Administration (Drugs@FDA), accessed 8 Oct 2026. accessdata.fda.gov
21. 21Warning letter to Royal Peptides LLC (MARCS-CMS 734884) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
22. 22Warning letter to Peptide Partners LLC (MARCS-CMS 735063) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
23. 23Warning letter to Peak Performance Peptides (MARCS-CMS 735127) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
24. 24Warning letter to Warrior Labz SARMS (MARCS-CMS 655280) U.S. Food and Drug Administration, 12 Jun 2023. fda.gov
25. 25Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
26. 26Former Connecticut Resident Guilty of Operating Websites to Illegally Sell Misbranded and Unapproved Drugs U.S. Attorney’s Office, District of Connecticut, 21 Sep 2026. justice.gov
27. 27Gobles Man Sentenced for Selling Chinese Drugs Without FDA Approval U.S. Attorney’s Office, Western District of Michigan, 23 Jul 2026. justice.gov
28. 28World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
29. 29Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
30. 30FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize U.S. Food and Drug Administration, 1 Apr 2026. fda.gov
31. 31The 2026 Monitoring Program World Anti-Doping Agency, Sep 2025. wada-ama.org
32. 32Drugs@FDA via openFDA: search for active ingredient cagrilintide (no matches) U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
33. 33FDA approves Novo Nordisk’s Wegovy pill, the first and only oral GLP-1 for weight loss in adults Novo Nordisk (PR Newswire), 22 Dec 2025. prnewswire.com
34. 34Outsourcing Facilities Ass’n v. FDA, No. 25-10758 (5th Cir.) (unpublished, per curiam; revised) US Court of Appeals for the Fifth Circuit, 1 Sep 2026. ca5.uscourts.gov
35. 35FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate) U.S. Food and Drug Administration, 5 Nov 2024. fda.gov
36. 36SAXENDA (liraglutide) injection: prescribing information (SPL version 22) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 15 Jun 2026. dailymed.nlm.nih.gov
37. 37Drugs@FDA: applications containing liraglutide (NDA 022341, NDA 206321, BLA 208583 and 11 ANDAs) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
38. 38FDA Drug Shortages: Liraglutide Injection U.S. Food and Drug Administration, accessed 7 Oct 2026. accessdata.fda.gov
39. 39Compounding when Drugs are on FDA’s Drug Shortages List U.S. Food and Drug Administration, 8 Aug 2025. fda.gov
40. 40World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
41. 41Voluntary Announcement: First Dual GCG/GLP-1 Receptor Agonist Mazdutide Received Approval by the National Medical Products Administration for Chronic Weight Management Innovent Biologics, Inc. (HKEXnews), 27 Jun 2025. www1.hkexnews.hk
42. 42Drugs@FDA via openFDA: search for active ingredient mazdutide (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
43. 43Mazdutide: First Approval Drugs, Dec 2025. pubmed.ncbi.nlm.nih.gov
44. 4421 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
45. 45WADA publishes 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
46. 46Approval letter for NDA 220934, Foundayo (orforglipron) tablets U.S. Food and Drug Administration, 1 Apr 2026. accessdata.fda.gov
47. 47Drugs@FDA: applications containing orforglipron (NDA 220934) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
48. 48Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes Boehringer Ingelheim (GlobeNewswire), 1 Oct 2026. globenewswire.com
49. 49Drugs@FDA via openFDA: search for active ingredient survodutide (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
50. 50The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 28 Jul 2026. thefdalawblog.com
51. 51Drugs@FDA via openFDA: search for active ingredients mechano growth factor and PEG-MGF (no matches) U.S. Food and Drug Administration (openFDA), accessed 8 Oct 2026. api.fda.gov · data query
52. 52FDA to Remove 12 Popular Peptides from the Category 2 ‘Do Not Compound’ List Frier Levitt, 16 Apr 2026. frierlevitt.com
53. 53Drugs@FDA via openFDA: search for active ingredients named pentadeca, BPC, bepecin or arginate (no matches) U.S. Food and Drug Administration (openFDA), 7 Oct 2026. api.fda.gov · data query
54. 54Final Award of Arbitrator, USADA v. a US short track speed skater (NE ADR Case Number 24062102) U.S. Anti-Doping Agency, 20 Aug 2024. usada.org
55. 55Drugs@FDA via openFDA: search for active ingredient thymosin or timbetasin (no matches) U.S. Food and Drug Administration (openFDA), 8 Oct 2026. api.fda.gov · data query
56. 56Warning letter to GenoGenix LLC (MARCS-CMS 718739) U.S. Food and Drug Administration, 20 Jan 2026. fda.gov
57. 57Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
58. 58The copper peptide trend has gone from creams to injections — ahead of the science NPR, 7 Sep 2026. npr.org
59. 59Drugs@FDA search for products containing prezatide (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 1 Oct 2026. api.fda.gov · data query
60. 60510(k) Premarket Notification K953853: Iamin Gel Wound Dressing (Procyte Corp.) U.S. Food and Drug Administration, 5 Feb 1996. accessdata.fda.gov
61. 61Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
62. 62Drugs@FDA data (openFDA drugsfda endpoint): search for melanotan as an active ingredient, no matches U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
63. 63Drugs@FDA: NDA 210797, Scenesse (afamelanotide) U.S. Food and Drug Administration (Drugs@FDA), accessed 7 Oct 2026. accessdata.fda.gov
64. 64Import Alert 66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. U.S. Food and Drug Administration, 1 Oct 2026. accessdata.fda.gov
65. 65EGRIFTA SV (tesamorelin) for injection: prescribing information (revised 2/2024) Theratechnologies via DailyMed (U.S. National Library of Medicine), Feb 2024. dailymed.nlm.nih.gov
66. 66EGRIFTA WR (tesamorelin) for injection: prescribing information (revised 3/2025) Theratechnologies via DailyMed (U.S. National Library of Medicine), Mar 2025. dailymed.nlm.nih.gov
67. 67Compounding and the FDA: Questions and Answers U.S. Food and Drug Administration, 16 Sep 2025. fda.gov
68. 68List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 U.S. Food and Drug Administration, accessed 1 Oct 2026. fda.gov
69. 69FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ipamorelin-related bulk drug substances (FDA evaluation dated 19 August 2024) U.S. Food and Drug Administration, 19 Aug 2024. fda.gov
70. 70FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: CJC-1295-related bulk drug substances U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
71. 71Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095) Federal Register (U.S. Food and Drug Administration), 4 Mar 2013. federalregister.gov
72. 72Drugs@FDA records for sermorelin acetate (Geref, NDA 019863 and NDA 020443), via the openFDA API U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
73. 73Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications (74 FR 23407) Federal Register (U.S. Food and Drug Administration), 19 May 2009. federalregister.gov
74. 74GHRP KAKEN100 Injection (注射用GHRP科研100): package insert, revised July 2025 (in Japanese) KEGG MEDICUS (JAPIC package insert data), Jul 2025. kegg.jp
75. 75Re-examination report for GHRP KAKEN100 Injection (注射用GHRP科研100, pralmorelin hydrochloride) (in Japanese) Pharmaceuticals and Medical Devices Agency (PMDA), Japan, 5 Feb 2014. pmda.go.jp
76. 76Drugs@FDA search for the active ingredient pralmorelin (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
77. 77Drugs@FDA search for active ingredients named GHRP (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
78. 78Drugs@FDA search for the active ingredient hexarelin (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
79. 79Drugs@FDA search for the active ingredient examorelin (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
80. 80FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ibutamoren mesylate (FDA evaluation dated 3 July 2024) U.S. Food and Drug Administration, 3 Jul 2024. fda.gov
81. 81Drugs@FDA record for NDA 210557 (Vyleesi), openFDA drugsfda endpoint U.S. Food and Drug Administration (openFDA), 29 Sep 2026. api.fda.gov · data query
82. 82Drugs@FDA via openFDA: applications containing gonadorelin (NDA 018123 Factrel, NDA 019687 Lutrepulse) U.S. Food and Drug Administration (openFDA), 7 Oct 2026. api.fda.gov · data query
83. 8321 CFR 522.1077, Gonadorelin (eCFR, as of 5 October 2026) Electronic Code of Federal Regulations (eCFR), 5 Oct 2026. ecfr.gov
84. 84USP Monographs: Gonadorelin Acetate (USP-NF, 2025 revision) United States Pharmacopeia, 2025. doi.usp.org
85. 85FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: kisspeptin-10 (FDA evaluation dated 5 July 2024) U.S. Food and Drug Administration, 5 Jul 2024. fda.gov
86. 86Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial American Journal of Cardiovascular Drugs, Jan 2026. pubmed.ncbi.nlm.nih.gov
87. 87Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure Reviews in Cardiovascular Medicine, Aug 2024. pubmed.ncbi.nlm.nih.gov
88. 88NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial The Laryngoscope, Mar 2026. pubmed.ncbi.nlm.nih.gov
89. 89Drugs@FDA via openFDA: search for active ingredient nadide or nicotinamide adenine dinucleotide (no matches) U.S. Food and Drug Administration (openFDA), 8 Oct 2026. api.fda.gov · data query
90. 90July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate); FDA evaluation dated 12 May 2026 U.S. Food and Drug Administration, Jul 2026. fda.gov
91. 91Search Orphan Drug Designations and Approvals: Epitalon (designated 2 September 2010; designation withdrawn or revoked 6 January 2016) U.S. Food and Drug Administration, accessed 5 Oct 2026. accessdata.fda.gov
92. 92Adverse Events Linked to Injectable Glutathione Compounded with Dietary Supplement Grade Ingredient: Current Situation U.S. Centers for Disease Control and Prevention, 15 Sep 2026. cdc.gov
93. 93FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent Food and Drug Administration Philippines, 5 Jul 2019. fda.gov.ph
94. 94Approval letter for NDA 215244, Forzinity (elamipretide) injection U.S. Food and Drug Administration, 19 Sep 2025. accessdata.fda.gov
95. 95Drugs@FDA record for NDA 215244 (Forzinity), openFDA drugsfda endpoint U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
96. 96Article 57 product data (EMA/518502/2018, Rev.89; data as present in the Article 57 database on 21 September 2026) European Medicines Agency, 21 Sep 2026. ema.europa.eu
97. 97About Cerebrolysin (product page with prescribing information and notice to U.S. visitors) EVER Neuro Pharma GmbH (maker of Cerebrolysin), 25 Jan 2024. cerebrolysin.com
98. 98Drugs@FDA via openFDA: search for active ingredient Cerebrolysin (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
99. 99Warning letter to Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine (MARCS-CMS 615908) U.S. Food and Drug Administration, 10 Nov 2021. fda.gov
100. 100Drugs@FDA API search for the active ingredient name ‘dihexa’ (no matches) openFDA, U.S. Food and Drug Administration, accessed 7 Oct 2026. api.fda.gov · data query
101. 101FDA Evaluation of Emideltide-Related Bulk Drug Substances (Emideltide (Free Base) and Emideltide Acetate), PCAC briefing document U.S. Food and Drug Administration, 11 May 2026. fda.gov
102. 102Дельтаран (Deltaran), nasal lyophilizate 0.3 mg: instructions for use Vidal Russia drug reference, 4 Jun 2026. vidal.ru
103. 103Дельтаран (Deltaran), nasal lyophilizate 0.3 mg: instructions, doses, side effects RLS (Register of Medicinal Products of Russia), 22 Sep 2026. rlsnet.ru
104. 104PITOCIN (oxytocin injection, USP) prescribing information Par Health USA, LLC via DailyMed (U.S. National Library of Medicine), 21 May 2026. dailymed.nlm.nih.gov
105. 105Drugs@FDA records for oxytocin (9 applications, including Pitocin NDA 018261 and Syntocinon nasal solution NDA 012285), openFDA drugsfda endpoint U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
106. 106Селанк (Selank) 0.15% nasal drops: instructions for use Vidal Russia drug reference, 22 Oct 2018. vidal.ru
107. 107Селанк (Selank) 0.15% nasal drops: instructions, doses, side effects RLS (Register of Medicinal Products of Russia), 15 Jul 2025. rlsnet.ru
108. 108Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 24 Feb 2021. justice.gov
109. 109FDA Evaluation of Semax-Related Bulk Drug Substances (Semax (Free Base) and Semax Acetate), PCAC briefing document U.S. Food and Drug Administration, 11 May 2026. fda.gov
110. 110Семакс (Semax) 1% nasal drops: instructions for use Vidal Russia drug reference, 18 Mar 2021. vidal.ru
111. 111Семакс (Semax) 0.1% nasal drops: instructions for use Vidal Russia drug reference, 17 Mar 2021. vidal.ru
112. 112FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate), Pharmacy Compounding Advisory Committee briefing document U.S. Food and Drug Administration, 12 May 2026. fda.gov
113. 113FDA presentations, July 23, 2026, Pharmacy Compounding Advisory Committee meeting U.S. Food and Drug Administration, 23 Jul 2026. fda.gov
114. 114Drugs@FDA API searches for the active ingredient names ‘ropocamptide’, ‘cathelicidin’ and ‘LL-37’ (no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
115. 115Тималин (Thymalin), lyophilizate for intramuscular injection 10 mg: instructions for use Vidal Russia drug reference, 25 Mar 2025. vidal.ru
116. 116Drugs@FDA via openFDA: search for active ingredient thymalin (no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
117. 117Banca Dati Farmaci: ZADAXIN (timosina alfa 1) 1.6 mg/ml powder and solvent for solution for injection, AIC 028364026 Agenzia Italiana del Farmaco (AIFA), accessed 5 Oct 2026. medicinali.aifa.gov.it
118. 118FDA Evaluation of Thymosin Alpha-1 (Ta1)-Related Bulk Drug Substances (Ta1 free base and Ta1 acetate), briefing document for the Pharmacy Compounding Advisory Committee meeting of December 4, 2024 U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
119. 119SciClone Pharmaceuticals 2014 Annual Report (Form 10-K for fiscal 2014) SciClone Pharmaceuticals, Inc., 12 Mar 2015. annualreports.com
120. 120Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 U.S. Food and Drug Administration, 21 Feb 2025. fda.gov
121. 121Drugs@FDA via openFDA: search for active ingredient aviptadil (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
122. 122Invicorp (injektionsvätska, lösning 25 mikrogram/2 mg): produktresumé (summary of product characteristics, Swedish) Evolan Pharma AB via FASS (Sweden), 9 Jul 2026. fass.se
123. 123AWMSG Secretariat Assessment Report: aviptadil/phentolamine mesilate (Invicorp) 25 micrograms/2 mg solution for injection, reference number 3435 All Wales Therapeutics and Toxicology Centre, May 2017. awttc.nhs.wales
124. 124List of new drugs approved in the year 2022 till date Central Drugs Standard Control Organisation, India, 2022. cdsco.gov.in
125. 125Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels U.S. Food and Drug Administration (company announcement), 1 Oct 2026. fda.gov
126. 126Generic Ozempic is now on Canadian shelves. Is it the same as the brand name version? CBC News, 20 May 2026. cbc.ca
127. 127Apo-Semaglutide Injection: Incorrect dose display Health Canada, 27 Aug 2026. recalls-rappels.canada.ca
128. 128Apo-Semaglutide Injection: Incorrect dose display (RA-82679) Health Canada, 25 Sep 2026. recalls-rappels.canada.ca
129. 129Outsourcing Facilities Ass’n v. FDA, No. 25-10600 (5th Cir.) (unpublished, per curiam) US Court of Appeals for the Fifth Circuit, 27 Aug 2026. ca5.uscourts.gov
130. 130Warning letter to TXP Innovations LLC dba Tex Peptides (MARCS-CMS 735067) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
131. 131No summer shortcut for safe weight loss Medicines and Healthcare products Regulatory Agency (GOV.UK), 24 Jul 2026. gov.uk
132. 132PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
133. 133Warning letter to Wholesale Peptide (MARCS-CMS 729447) U.S. Food and Drug Administration, 17 Jun 2026. fda.gov
134. 134Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
135. 13521 CFR Part 1308, Schedules of Controlled Substances (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
136. 136Medicines watchdog to investigate UK peptide clinics over health claims The Guardian, 4 Apr 2026. theguardian.com
137. 137July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
138. 138Federal Register search: FDA documents mentioning “503A” published since 1 July 2026 Federal Register, accessed 8 Oct 2026. federalregister.gov
139. 139Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024 U.S. Food and Drug Administration, 15 Jan 2025. fda.gov
140. 140US 9,850,282 B2: Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy U.S. Patent and Trademark Office, 26 Dec 2017. image-ppubs.uspto.gov
141. 141Meeting of the Pharmacy Compounding Advisory Committee (to be held before the end of February 2027) U.S. Food and Drug Administration, 15 Apr 2026. fda.gov
142. 142NDA 022341 approval letter (Victoza) U.S. Food and Drug Administration, 25 Jan 2010. accessdata.fda.gov
143. 143NDA 206321 approval letter (Saxenda) U.S. Food and Drug Administration, 23 Dec 2014. accessdata.fda.gov
144. 144VYLEESI (bremelanotide injection) prescribing information Cosette Pharmaceuticals via DailyMed (U.S. National Library of Medicine), 13 Nov 2025. dailymed.nlm.nih.gov
145. 145Oxytocin Nasal Spray for Stress Reduction, Heart Health, and Longevity Healthspan (telehealth seller), accessed 7 Oct 2026. gethealthspan.com (seller page, deliberately not linked)
146. 146FORZINITY (elamipretide) injection prescribing information Stealth BioTherapeutics via DailyMed (U.S. National Library of Medicine), 10 Dec 2025. dailymed.nlm.nih.gov
147. 147SCENESSE (afamelanotide) implant prescribing information Clinuvel via DailyMed (U.S. National Library of Medicine), 11 May 2026. dailymed.nlm.nih.gov
148. 148Approval letter for NDA 210797, Scenesse (afamelanotide) implant U.S. Food and Drug Administration, 8 Oct 2019. accessdata.fda.gov
149. 149Factrel (Gonadorelin): Side Effects, Uses, Dosage, Interactions, Warnings RxList, 8 Aug 2022. rxlist.com
150. 150A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump: clinical trial protocol, amendment 7 (NCT01976728) Ferring Pharmaceuticals, via ClinicalTrials.gov, 6 Dec 2017. cdn.clinicaltrials.gov
151. 151Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company (PR Newswire), 23 Jul 2026. prnewswire.com
152. 152Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026 Novo Nordisk A/S (GlobeNewswire), 30 Sep 2026. globenewswire.com
153. 153The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology, 18 Jun 2026. frontiersin.org
154. 154Triathlon Athlete Accepts Sanction for Anti-Doping Rule Violations U.S. Anti-Doping Agency, 17 Sep 2025. usada.org
155. 155BPC-157: Experimental Peptide Creates Risk for Athletes U.S. Anti-Doping Agency, 10 Aug 2026. usada.org
156. 156Scenesse: EPAR product information European Medicines Agency, 7 Oct 2026. ema.europa.eu
157. 157A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides Neuroscience & Medicine (Scientific Research Publishing), Dec 2013. scirp.org
158. 158Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (F2024L00589) Federal Register of Legislation, Australian Government, 28 May 2024. legislation.gov.au
159. 159Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings ABC News (Australia), 14 Sep 2026. abc.net.au
160. 160TGA tests counterfeit retatrutide product following serious adverse event report Pharmacy Today, 15 Sep 2026. pharmacytoday.co.nz
161. 161MT2 ‘Barbie-tan’ peptide warning as TGA seizes nasal spray with wildly different doses 7NEWS (Australia), 18 Aug 2026. 7news.com.au
162. 162MHRA smashes major illicit weight loss medicine production facility in record seizure Medicines and Healthcare products Regulatory Agency (GOV.UK), 24 Oct 2025. gov.uk
163. 163Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks (RA-77218) Health Canada, 1 Apr 2025. recalls-rappels.canada.ca
164. 164GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients (RA-82047) Health Canada, 7 May 2026. recalls-rappels.canada.ca
165. 165Prescription Drug List: Human Use Health Canada (Drug and Health Product Register), accessed 8 Oct 2026. hpr-rps.hres.ca
166. 166Drug Product Database API: active ingredient search for gonadorelin (16 products; status checked in each product record) Health Canada, accessed 8 Oct 2026. health-products.canada.ca · data query
167. 167Weightlifting Athlete Accepts Sanction for Anti-Doping Rule Violations U.S. Anti-Doping Agency, 20 Feb 2026. usada.org